Samuel Ray Denmeade is a Professor of Oncology, Urology and Pharmacology and Molecular Sciences at the Johns Hopkins University School of Medicine. Over 10 of his published papers have each been cited over 100 times.
The American Association for Cancer Research (AACR) is the world's oldest and largest professional association related to cancer research. Based in Philadelphia, the AACR focuses on all aspects of cancer research, including basic, clinical, and translational research into the etiology, prevention, diagnosis, and treatment of cancer. Founded in 1907 by 11 physicians and scientists, the organization now has more than 52,000 members in 130 countries and territories. The mission of the AACR is to prevent and cure cancer through research, education, communication, collaboration, science policy and advocacy, and funding for cancer research.
Targeted therapy or molecularly targeted therapy is one of the major modalities of medical treatment (pharmacotherapy) for cancer, others being hormonal therapy and cytotoxic chemotherapy. As a form of molecular medicine, targeted therapy blocks the growth of cancer cells by interfering with specific targeted molecules needed for carcinogenesis and tumor growth, rather than by simply interfering with all rapidly dividing cells. Because most agents for targeted therapy are biopharmaceuticals, the term biologic therapy is sometimes synonymous with targeted therapy when used in the context of cancer therapy. However, the modalities can be combined; antibody-drug conjugates combine biologic and cytotoxic mechanisms into one targeted therapy.
The British Journal of Cancer is a twice-monthly professional medical journal owned by Cancer Research UK, published on their behalf by Springer Nature's Nature Research.
Cancer and Leukemia Group B is a cancer research cooperative group in the United States.
John Gordon McVie was an international authority on the treatment and research of cancer. He wrote over 350 peer-reviewed articles, editorials and books. McVie was born in Glasgow, Scotland and died of non-Hodgkin lymphona and COVID-19 in Bristol, England.
Clinical Lung Cancer is a peer-reviewed medical journal that has been published by Elsevier since 2011. It was established by the CIG Media Group in 1999.
Allied Academies is a reportedly fraudulent corporation chartered under the laws of North Carolina. Its postal address is in London, United Kingdom. It presents itself as an association of scholars, with supporting and encouraging research and the sharing and exchange of knowledge as its stated aims. The organization consists of 30 affiliate academies, which provide awards to academics and publish academic journals both online and in hard copy for members. Since 2015 the organization has been listed on Jeffrey Beall's list of "potential, possible, or probable predatory scholarly open-access publishers". It is in a partnership with OMICS Publishing Group which uses its website and logo. In 2018, OMICS owner Srinubabu Gedela declared that he had informed the Nevada court that Allied Academies was a subsidiary of OMICS International. During a conference in 2018, they falsely listed a prominent chemist among its organizing committee who had not agreed to this and was not affiliated with Allied Academies.
Hani Gabra PhD FRCPE FRCP is a British oncologist and Professor Emeritus in Medical Oncology at Imperial College London.
Tower Cancer Research Foundation (TCRF) is a 501(c)3 non-profit organization dedicated to clinical research, patient support and community education. It was established in 1996 in Beverly Hills, California.
John Mendelsohn was a president of the University of Texas MD Anderson Cancer Center in Houston. He was an internationally recognized leader in cancer research.
Current Cancer Drug Targets is a peer-reviewed medical journal published by Bentham Science Publishers. The editor-in-chief is Ruiwen Zhang. The journal covers research on contemporary molecular drug targets involved in cancer, including medicinal chemistry, pharmacology, molecular biology, genomics, and biochemistry. Current Cancer Drug Targets publishes original research reports, review papers, and rapid communications ("letters").
William Douglas Figg is an American scientist (pharmacologist). He is a senior investigator (tenured) at the National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, Maryland. He holds multiple titles within the NCI: Associate Director of the Center for Cancer Research, Co-Director of the Office of Translational Resources, Acting Branch Chief for the Genitourinary Malignancies Branch, Chief of the Clinical Pharmacology Program, and head of the Molecular Pharmacology Section. Dr. Figg is also the Co-Chief of Basic Research at the Center for Prostate Disease Research within the Walter Reed National Military Medical Center – Murtha Cancer Center in Bethesda, Maryland.
The Edinburgh Cancer Research Centre (ECRC), also known as the Cancer Research UK Edinburgh Centre and the University of Edinburgh Cancer Research Centre, is a center for basic, translational and clinical cancer research located in Edinburgh, Scotland. ECRC constitutes a part of the Institute of Genetics & Molecular Medicine (IGMM) and is positioned in direct proximity of the Western General Hospital, where most of its clinical activities take place.
Thomas E. Hutson is an American medical oncologist and cancer researcher based in Dallas, Texas. He is the director of Genitourinary Oncology Program and co-director of the Urologic Cancer Research and Treatment Center at Baylor University Medical Center. He is a Professor of Medicine at the Texas A&M Health Science Center College of Medicine and serves as a chair of Genitourinary Research for US Oncology and McKesson.
Richard Malcolm Marais is Director of the Cancer Research UK (CRUK) Manchester Institute and Professor of Molecular Oncology at the University of Manchester.
Sun Yat-sen University Cancer Center, abbreviated as SYSUCC, is a public hospital in Guangzhou, China. It is affiliated with Sun Yat-sen University.
Jason S. Lewis is a British radiochemist whose work relates to oncologic therapy and diagnosis. His research focus is a molecular imaging-based program focused on radiopharmaceutical development as well as the study of multimodality small- and biomolecule-based agents and their clinical translation. He has worked on the development of small molecules as well as radiolabeled peptides and antibodies probing the overexpression of receptors and antigens on tumors.
